Royal London Asset Management
RVMD icon

Royal London Asset Management’s Revolution Medicines RVMD Stock Holding History

Royal London Asset Management’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$713K Buy
3,808
+666
+21% +$97.3K ﹤0.01% 625
2026
Q1 		$306K Buy
+3,142
New +$317K ﹤0.01% 660

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Royal London Asset Management's RVMD Position: Q2 2026 in Review

Royal London Asset Management increased its Revolution Medicines (RVMD) stake by 21% in Q2 2026, buying an estimated $97.3K and bringing the position to 3,808 shares worth $713K. The position accounts for ﹤0.01% of the portfolio, ranked #625.

Royal London Asset Management first reported a position in RVMD in Q1 2026 and has held it in 2 quarters since. 693 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Royal London Asset Management held 3,808 shares of Revolution Medicines worth $713K as of Q2 2026.
  • Royal London Asset Management bought 666 Revolution Medicines shares in Q2 2026, an estimated $97.3K.
  • Revolution Medicines made up ﹤0.01% of Royal London Asset Management's portfolio in Q2 2026, its #625 holding.
  • Royal London Asset Management first reported a position in Revolution Medicines in Q1 2026 and has held it in 2 quarters since.
  • 693 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Royal London Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.